Active Surveillance or Watchful Waiting – How do They Apply to Your Patients?

00:00 1.
Active Surveillance or Watchful Waiting – How do They Apply to Your Patients?
00:21 2.
大部分攝護腺癌病人死於其他疾病
01:17 3.
Radical Prostatectomy vs Observation for Localized Prostate Cancer (PIVOT study)
03:13 4.
Radical Prostatectomy vs WW for Localized Prostate Cancer (SPCG-4)
04:04 5.
Are Results of PIVOT contradictory to SPCG-4?
05:27 6.
National Taiwan Cancer Registry (2008~2010)
06:00 7.
Watchful Waiting vs Active Surveillance
07:04 8.
Clinical Case 1
07:49 9.
Clinical Case 1
08:19 10.
Clinical Case 1
09:25 11.
Clinical Case 1
10:09 12.
Active Surveillance: Advantages vs Disadvantages
11:32 13.
Observation (Watchful Waiting): Advantages vs Disadvantages
12:06 14.
Selection Criteria for Active Surveillance
13:00 15.
Follow-up Protocol for AS
13:34 16.
Progression Criteria
14:05 17.
Clinical Series with Active SurveillanceEAU Guideline 2014
14:52 18.
Long-Term Follow-Up of an Active Surveillance Cohort
15:46 19.
Taiwan Prostate Cancer Database ConsortiumOverall Survival by Stage
16:17 20.
Taiwan Prostate Cancer Database ConsortiumCancer-Specific Survival by Stage
17:06 21.
Taiwan Prostate Cancer Database ConsortiumTreatments (Localized, T1-3N0M0)
19:33 22.
Conclusions

未登入或權限不足!

00:00 1.
Active Surveillance or Watchful Waiting – How do They Apply to Your Patients?
00:21 2.
大部分攝護腺癌病人死於其他疾病
01:17 3.
Radical Prostatectomy vs Observation for Localized Prostate Cancer (PIVOT study)
03:13 4.
Radical Prostatectomy vs WW for Localized Prostate Cancer (SPCG-4)
04:04 5.
Are Results of PIVOT contradictory to SPCG-4?
05:27 6.
National Taiwan Cancer Registry (2008~2010)
06:00 7.
Watchful Waiting vs Active Surveillance
07:04 8.
Clinical Case 1
07:49 9.
Clinical Case 1
08:19 10.
Clinical Case 1
09:25 11.
Clinical Case 1
10:09 12.
Active Surveillance: Advantages vs Disadvantages
11:32 13.
Observation (Watchful Waiting): Advantages vs Disadvantages
12:06 14.
Selection Criteria for Active Surveillance
13:00 15.
Follow-up Protocol for AS
13:34 16.
Progression Criteria
14:05 17.
Clinical Series with Active SurveillanceEAU Guideline 2014
14:52 18.
Long-Term Follow-Up of an Active Surveillance Cohort
15:46 19.
Taiwan Prostate Cancer Database ConsortiumOverall Survival by Stage
16:17 20.
Taiwan Prostate Cancer Database ConsortiumCancer-Specific Survival by Stage
17:06 21.
Taiwan Prostate Cancer Database ConsortiumTreatments (Localized, T1-3N0M0)
19:33 22.
Conclusions

長度: 38:19, 瀏覽: 838, 最近修訂: 2017-05-19

00:00 1.
Active Surveillance or Watchful Waiting – How do They Apply to Your Patients?
00:21 2.
大部分攝護腺癌病人死於其他疾病
01:17 3.
Radical Prostatectomy vs Observation for Localized Prostate Cancer (PIVOT study)
03:13 4.
Radical Prostatectomy vs WW for Localized Prostate Cancer (SPCG-4)
04:04 5.
Are Results of PIVOT contradictory to SPCG-4?
05:27 6.
National Taiwan Cancer Registry (2008~2010)
06:00 7.
Watchful Waiting vs Active Surveillance
07:04 8.
Clinical Case 1
07:49 9.
Clinical Case 1
08:19 10.
Clinical Case 1
09:25 11.
Clinical Case 1
10:09 12.
Active Surveillance: Advantages vs Disadvantages
11:32 13.
Observation (Watchful Waiting): Advantages vs Disadvantages
12:06 14.
Selection Criteria for Active Surveillance
13:00 15.
Follow-up Protocol for AS
13:34 16.
Progression Criteria
14:05 17.
Clinical Series with Active SurveillanceEAU Guideline 2014
14:52 18.
Long-Term Follow-Up of an Active Surveillance Cohort
15:46 19.
Taiwan Prostate Cancer Database ConsortiumOverall Survival by Stage
16:17 20.
Taiwan Prostate Cancer Database ConsortiumCancer-Specific Survival by Stage
17:06 21.
Taiwan Prostate Cancer Database ConsortiumTreatments (Localized, T1-3N0M0)
19:33 22.
Conclusions

位置

資料夾名稱

2015臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2017-05-19 17:02:08

最近修訂

2017-05-19 19:21:05

長度

38:19